Corcept Therapeutics Incorporated (CORT) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Corcept Therapeutics Incorporated (CORT) Healthcare & Pipeline Overview

Corcept Therapeutics Incorporated is a U.S.-based biotechnology firm specializing in therapies for severe metabolic, oncologic, and neuropsychiatric disorders, leveraging its commercialized drug Korlym for Cushing's syndrome and advancing a pipeline of selective cortisol modulators for various unmet medical needs. The company maintains a high gross margin of 98.3% and a market capitalization of $12.9B.

What Is the Investment Thesis for CORT?

Corcept Therapeutics Incorporated presents a focused investment thesis centered on its established commercial product, Korlym, and a pipeline of cortisol modulators targeting significant unmet medical needs. The company's financial profile, characterized by a robust gross margin of 98.3% and a profit margin of 6.2%, underscores the profitability of its existing operations. With a market capitalization of $12.9B, Corcept demonstrates a strong market presence within the biotechnology sector. The ongoing development of relacorilant for Cushing's syndrome, alongside the nab-paclitaxel and relacorilant combination for advanced ovarian tumors, represents key growth catalysts. The progression of these clinical programs, particularly the Phase II completion for ovarian tumors, could unlock new revenue streams and expand Corcept's therapeutic footprint. Further value drivers include selective cortisol modulators in development for metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, addressing large patient populations. While the debt-to-equity ratio of 1.51 indicates leverage, the company's strong gross margin and ongoing R&D efforts position it for potential long-term value creation, contingent on successful clinical development and regulatory approvals.

Based on FMP financials and quantitative analysis

CORT Key Highlights

Market capitalization of $12.9B, reflecting its valuation within the biotechnology sector.

• Exceptional gross margin of 98.3%, indicating strong cost control and pricing power for its commercialized product, Korlym.
• Profit margin of 6.2%, demonstrating the company's ability to generate net income from its revenue.
• Return on Equity (ROE) of 7.2%, showcasing its efficiency in generating profits from shareholders' equity.
• Debt-to-equity ratio of 1.51, indicating a reliance on debt financing relative to equity, which is common in R&D-intensive industries like biotechnology.

Who Are CORT's Competitors?

CORT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CORT's Key Strengths?

Commercialized product Korlym with a high gross margin of 98.3%, providing a stable revenue base.

• Specialized focus on cortisol modulation, creating expertise in a niche but impactful therapeutic area.
• Diversified pipeline targeting multiple severe metabolic, oncologic, and neuropsychiatric disorders.
• Strong R&D capabilities, evidenced by multiple compounds in various stages of clinical development.
• Headquartered in Menlo Park, California, a hub for biotechnology innovation.

What Are CORT's Weaknesses?

Reliance on a single commercialized product, Korlym, for current revenue generation.

• High debt-to-equity ratio of 1.51, indicating significant leverage.
• Pipeline products are in various stages of clinical development, with inherent risks of failure.
• Limited geographic reach, with current commercialization primarily in the United States.
• Relatively small employee base (500 employees) for a company with a broad pipeline.

What Could Drive CORT Stock Higher?

CORT catalyst: **Relacorilant Clinical Trial Readouts:** Positive data readouts from ongoing clinical trials for relacorilant in Cushing's syndrome could significantly de-risk the program and pave the way for regulatory filings, potentially expanding Corcept's market presence in this therapeutic area.

• **Advancement of Oncology Pipeline:** Progression of the nab-paclitaxel and relacorilant combination therapy beyond Phase II for advanced ovarian tumors, or the selective cortisol modulator for metastatic castration-resistant prostate cancer into later-stage trials, would signal significant potential for new revenue streams in oncology.
• **Regulatory Milestones for Pipeline Candidates:** Achievement of key regulatory milestones, such as Fast Track designation, Breakthrough Therapy designation, or submission of New Drug Applications (NDAs) for any of its pipeline assets, would indicate significant progress towards commercialization.
• **Commercial Performance of Korlym:** Continued strong sales performance and market penetration of Korlym for Cushing's syndrome will provide a stable financial foundation and support ongoing R&D investments.
• **Neuropsychiatric Program Development:** Initial clinical data or significant progress in the development of the selective cortisol modulator for antipsychotic-induced weight gain and other disorders could open up a large new market opportunity for the company.

What Are the Key Risks for CORT?

Rich valuation — a P/E of 170.3 runs well above the Healthcare sector’s ~23x, leaving little room for a miss.

• Insider selling — insiders were net sellers of roughly $13.4M recently.
• **Clinical Trial Failures:** The failure of any of Corcept's pipeline candidates, such as relacorilant or its oncology programs, to meet primary endpoints in clinical trials could significantly impact future growth prospects and investor confidence.
• **Regulatory Delays or Non-Approval:** Delays in regulatory review or the inability to obtain approval from health authorities for new drug candidates could defer or prevent market entry, impacting potential revenue generation.
• **Intense Competition:** The biotechnology sector is highly competitive. New therapies from competitors or existing treatments gaining broader adoption could limit the market potential for Corcept's current and future products.
• **Intellectual Property Challenges:** Challenges to the validity or scope of Corcept's patents for Korlym or its pipeline compounds could lead to generic competition or limit market exclusivity, impacting profitability.
• **Market Acceptance and Reimbursement:** Even if approved, new drugs may face challenges in gaining market acceptance from physicians and patients, or securing favorable reimbursement from payers, which could limit sales volumes.

What Are the Growth Opportunities for CORT?

• **Expansion in Cushing's Syndrome Treatment with Relacorilant:** Corcept is actively developing relacorilant, a selective cortisol modulator, to treat patients with Cushing's syndrome. This represents a significant growth opportunity by potentially offering an alternative or complementary treatment option to Korlym, expanding Corcept's market share within this rare disease. The market for Cushing's syndrome treatments, while niche, addresses a critical need for patients who may not respond to or be candidates for surgery. Successful development and commercialization of relacorilant could solidify Corcept's leadership in this therapeutic area, potentially capturing a larger segment of the patient population and driving revenue growth through a diversified product offering in the coming years.
• **Entry into Oncology with Nab-Paclitaxel and Relacorilant Combination:** The company has completed Phase II clinical trials for a combination of nab-paclitaxel and relacorilant for the treatment of advanced ovarian tumors. This initiative marks a strategic expansion into the oncology market, a substantially larger and high-value therapeutic area. Ovarian cancer represents a significant unmet medical need, particularly in advanced stages. Successful progression through later-stage clinical trials and regulatory approval for this combination therapy could unlock a substantial new revenue stream for Corcept, diversifying its product portfolio beyond metabolic disorders and establishing a foothold in cancer treatment within the next five to ten years, contingent on trial outcomes.
• **Targeting Metastatic Castration-Resistant Prostate Cancer (mCRPC):** Corcept is developing a selective cortisol modulator specifically for the treatment of metastatic castration-resistant prostate cancer. mCRPC is a challenging and aggressive form of prostate cancer with a high unmet medical need for new therapeutic options. The market for mCRPC treatments is substantial, driven by an aging population and the progression of prostate cancer. Successful development and commercialization of this modulator could provide Corcept with access to a large patient population and a significant revenue opportunity, positioning the company in a competitive oncology segment over the long term, subject to clinical success and regulatory milestones.
• **Addressing Antipsychotic-Induced Weight Gain and Other Disorders:** Another selective cortisol modulator is under development for the treatment of antipsychotic-induced weight gain and other related disorders. Antipsychotic-induced weight gain is a common and serious side effect of many psychiatric medications, leading to significant health complications and reduced treatment adherence. This represents a broad market opportunity, as millions of individuals worldwide are prescribed antipsychotics. A successful therapy could significantly improve patient outcomes and quality of life, offering a substantial commercial opportunity for Corcept in the neuropsychiatric space, potentially within the next decade, pending clinical development and market acceptance.
• **Leveraging FKBP5 Gene Expression Assays:** Corcept is developing FKBP5 gene expression assays, which could serve as valuable diagnostic or prognostic tools. While not a direct therapeutic product, these assays could enhance the company's precision medicine capabilities, potentially aiding in patient selection for its cortisol modulator therapies or identifying individuals at risk for certain conditions. This opportunity lies in strengthening Corcept's research and development infrastructure, potentially leading to more targeted and effective drug development, and could also open avenues for licensing or partnerships, contributing to long-term value creation by improving the efficiency and success rates of its clinical programs.

What Are CORT's Competitive Advantages?

• Proprietary drug Korlym (mifepristone) for a specific indication in Cushing's syndrome, providing market exclusivity.
• Specialized expertise in cortisol modulation, allowing for targeted drug discovery and development in related disorders.
• Extensive clinical trial data and regulatory approvals for its commercialized product, creating a barrier to entry for new competitors.
• Pipeline of novel selective cortisol modulators, which could lead to new patented therapies in oncology and neuropsychiatry.
• Intellectual property protection for its drug compounds and development programs, safeguarding its innovations.

What Does CORT Do?

Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a biotechnology company dedicated to the discovery, development, and commercialization of innovative drugs for severe metabolic, oncologic, and neuropsychiatric disorders within the United States. The company's foundational product, Korlym (mifepristone) tablets, represents a significant advancement in the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome. This once-daily oral medication is specifically indicated for individuals who have type 2 diabetes mellitus or glucose intolerance and have either failed surgery or are not candidates for surgical intervention, addressing a critical unmet medical need in a complex patient population. Since its incorporation, Corcept Therapeutics has strategically evolved its focus, building a robust pipeline centered around cortisol modulation. Beyond Korlym, the company is actively developing relacorilant, another promising candidate aimed at treating patients with Cushing's syndrome, which could expand its market presence in this therapeutic area. Furthermore, Corcept is exploring novel applications for its compounds in oncology, with nab-paclitaxel in combination with relacorilant having completed Phase II clinical trials for advanced ovarian tumors, indicating a potential expansion into cancer treatment. This combination therapy is also being investigated for broader applications in treating cortisol excess. The company's research and development efforts extend to other selective cortisol modulators, including one in development for metastatic castration-resistant prostate cancer and another for antipsychotic-induced weight gain and other related disorders, showcasing a diversified approach to addressing conditions linked to cortisol dysregulation. Additionally, Corcept is developing FKBP5 gene expression assays, which could serve as diagnostic or prognostic tools, further solidifying its position in precision medicine within its therapeutic areas.

What Products and Services Does CORT Offer?

• Discover, develop, and commercialize drugs for severe metabolic, oncologic, and neuropsychiatric disorders.
• Offer Korlym (mifepristone) for hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome.
• Develop relacorilant for the treatment of Cushing's syndrome, expanding their core therapeutic area.
• Advance nab-paclitaxel in combination with relacorilant for advanced ovarian tumors and general cortisol excess.
• Research selective cortisol modulators for metastatic castration-resistant prostate cancer.
• Develop selective cortisol modulators to address antipsychotic-induced weight gain and other related conditions.
• Create FKBP5 gene expression assays for potential diagnostic or prognostic applications.

How Does CORT Make Money?

• Generate revenue through the commercial sales of Korlym (mifepristone) tablets for Cushing's syndrome in the United States.
• Invest in extensive research and development to discover and advance new drug candidates through preclinical and clinical trial phases.
• Seek regulatory approvals from health authorities like the FDA for new drug candidates to bring them to market.
• Potentially license or partner with other pharmaceutical companies for the development or commercialization of pipeline assets in specific markets or therapeutic areas.
• Monetize intellectual property through patents protecting its drug compounds and formulations.

What Industry Does CORT Operate In?

Corcept Therapeutics operates within the highly specialized and competitive Biotechnology industry, a sub-sector of Healthcare, focusing on severe metabolic, oncologic, and neuropsychiatric disorders. This industry is characterized by extensive research and development, lengthy clinical trial processes, and significant regulatory hurdles. Corcept's niche in cortisol modulation positions it in a market segment with specific, often rare, disease populations, such as endogenous Cushing's syndrome, where Korlym is already commercialized. The broader biotechnology market is driven by advancements in genomics, personalized medicine, and an increasing understanding of disease mechanisms, leading to targeted therapies. Competitive pressures arise from both established pharmaceutical giants and other innovative biotech firms developing novel treatments. Corcept's strategy involves leveraging its expertise in cortisol biology to develop differentiated therapies, aiming to capture market share in areas with high unmet medical needs and limited treatment options, thereby navigating the intense competitive landscape through specialized innovation.

Who Are CORT's Key Customers?

• Adult patients diagnosed with endogenous Cushing's syndrome who experience hyperglycemia secondary to hypercortisolism, particularly those with type 2 diabetes mellitus or glucose intolerance, and who have failed surgery or are not surgical candidates.
• Healthcare providers, including endocrinologists, oncologists, and psychiatrists, who prescribe or administer treatments for severe metabolic, oncologic, and neuropsychiatric disorders.
• Hospitals, clinics, and specialized treatment centers that manage patients with complex endocrine, cancer, and mental health conditions.
• Potentially, patients with advanced ovarian tumors, metastatic castration-resistant prostate cancer, or antipsychotic-induced weight gain, upon successful development and commercialization of pipeline products.

Company Profile

Corcept Therapeutics Incorporated operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Redwood City, US. The company is led by CEO Joseph K. Belanoff. CORT has traded publicly since 2004.

How Corcept Therapeutics Incorporated Is Valued

Corcept Therapeutics Incorporated carries a market capitalization of $12.9B, placing it in the large-cap category. Relative to its peer group, CORT's quantitative score of 96/100 is above the peer average of 71/100.

Return on equity for Corcept Therapeutics Incorporated stands at 7.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 5.9%, showing how much profit it generates from its asset base. CORT trades at a trailing price-to-earnings ratio of 170.31, above the Healthcare sector average of ~23x. Its free cash flow yield is 1.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.86 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 0.6%, the inverse of the P/E and a quick read on earnings relative to price.

Corcept Therapeutics Incorporated's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 44.32 places it in the safe zone, indicating low near-term bankruptcy risk.

Wall Street analysts project Corcept Therapeutics Incorporated revenue of about $1.08B for fiscal 2026, with EPS near $2.02. The estimate reflects 3 contributing analysts.

Over the past six months, Corcept Therapeutics Incorporated insiders filed 30 SEC Form 4 transactions — 25 sales and 5 purchases. On net that is roughly 108K shares disposed (about $13.4M), a signal worth weighing alongside the fundamentals.

CORT Financials

CORT Latest News

CORT Analyst Consensus

CORT MoonshotScore

Latest Corcept Therapeutics Incorporated Analysis

Common Questions About CORT (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources